These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30119082)

  • 1. Bevacizumab in Cervical Cancer: 5 Years After.
    Pfaendler KS; Liu MC; Tewari KS
    Cancer J; 2018; 24(4):187-192. PubMed ID: 30119082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.
    Eskander RN; Tewari KS
    Future Oncol; 2015; 11(6):909-22. PubMed ID: 25760973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. bevacizumab (Avastin°) in persistent, recurrent or metastatic cervical cancer: Prolongs survival by a few months, but highly toxic.
    Prescrire Int; 2016 Oct; 25(175):233. PubMed ID: 30645824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review.
    Raouf S; Bertelli G; Ograbek A; Field P; Tran I
    Future Oncol; 2019 Feb; 15(5):543-561. PubMed ID: 30379088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab and Glioblastoma: Past, Present, and Future Directions.
    Kim MM; Umemura Y; Leung D
    Cancer J; 2018; 24(4):180-186. PubMed ID: 30119081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab in advanced lung cancer: state of the art.
    Assoun S; Brosseau S; Steinmetz C; Gounant V; Zalcman G
    Future Oncol; 2017 Dec; 13(28):2515-2535. PubMed ID: 28812378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.
    Minion LE; Bai J; Monk BJ; Robin Keller L; Ramez EN; Forde GK; Chan JK; Tewari KS
    Gynecol Oncol; 2015 Jun; 137(3):490-6. PubMed ID: 25766118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
    Haunschild CE; Tewari KS
    Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab Efficacy and Recurrence Pattern of Persistent and Metastatic Cervical Cancer.
    Lee N; Kim SI; Lee M; Kim HS; Kim JW; Park NH; Song YS
    In Vivo; 2019; 33(3):863-868. PubMed ID: 31028209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
    Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
    Minion LE; Tewari KS
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer.
    Tewari KS; Monk BJ
    Clin Adv Hematol Oncol; 2014 Nov; 12(11):737-48. PubMed ID: 25674713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction by the Guest Editors: Bevacizumab.
    Ferrara N; Chen DS
    Cancer J; 2018; 24(4):163-164. PubMed ID: 30119078
    [No Abstract]   [Full Text] [Related]  

  • 14. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
    Krill LS; Tewari KS
    Expert Opin Pharmacother; 2015 Apr; 16(5):675-83. PubMed ID: 25643984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.
    Alldredge JK; Tewari KS
    Oncologist; 2016 May; 21(5):576-85. PubMed ID: 27026677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab for the treatment of cervical cancer.
    Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
    Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Not Available].
    Kurtz JE; D'Hondt V; Lécuru F; Lhommé C
    Bull Cancer; 2017 May; 104 Suppl 1():S39-S42. PubMed ID: 28625314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term curative effect and safety of bevacizumab combined with chemotherapy for treating recurrent and metastatic cervical cancer.
    Xiao Y; Cheng HJ; Wang L; Luo SX
    Eur J Gynaecol Oncol; 2017; 38(1):76-79. PubMed ID: 29767869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer.
    Krill LS; Tewari KS
    Clin Ther; 2015 Jan; 37(1):9-19. PubMed ID: 25592088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.